Bavituximab
From Wikipedia, the free encyclopedia
|
Bavituximab
|
|
|
|
|
| Source | chimeric |
| Target | 3G4, 2aG4 |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Bavituximab is a chimeric monoclonal antibody which it's used to treat cancers. It binds to 3G4, 2aG4.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Abciximab, Basiliximab, Bavituximab, Cetuximab, Clenoliximab, Ecromeximab, Galiximab, Gomiliximab, Infliximab, Keliximab, Lumiliximab, Pagibaximab, Rituximab, Teneliximab, Vapaliximab, Volociximab
